In ACS acute tx, which antiplatelet combination is typical?

In ACS acute tx, which antiplatelet combination is typical?

• A. Clopidogrel alone
• B. Aspirin + a P2Y12 inhibitor
• C. No antiplatelet therapy
• D. Aspirin alone

Answer: (B)

In acute coronary syndrome, the aim is rapid and strong inhibition of platelet activation to prevent clot growth and recurrent ischemia. The typical approach is dual antiplatelet therapy: aspirin, which irreversibly blocks platelet COX-1 and reduces thromboxane A2 formation, plus a P2Y12 receptor inhibitor that prevents ADP-mediated platelet activation and aggregation. Using both targets the two main pathways of platelet activation, giving a more robust antithrombotic effect than either agent alone. Clopidogrel alone wouldn’t address the rapid ADP-driven activation that aspirin doesn’t fully inhibit, and aspirin alone leaves a significant residual risk. Omitting antiplatelet therapy in ACS markedly increases the risk of recurrent events. Therefore, the standard combo is aspirin plus a P2Y12 inhibitor (options include clopidogrel, prasugrel, or ticagrelor, chosen based on clinical context).

In acute coronary syndrome, the aim is rapid and strong inhibition of platelet activation to prevent clot growth and recurrent ischemia. The typical approach is dual antiplatelet therapy: aspirin, which irreversibly blocks platelet COX-1 and reduces thromboxane A2 formation, plus a P2Y12 receptor inhibitor that prevents ADP-mediated platelet activation and aggregation. Using both targets the two main pathways of platelet activation, giving a more robust antithrombotic effect than either agent alone. Clopidogrel alone wouldn’t address the rapid ADP-driven activation that aspirin doesn’t fully inhibit, and aspirin alone leaves a significant residual risk. Omitting antiplatelet therapy in ACS markedly increases the risk of recurrent events. Therefore, the standard combo is aspirin plus a P2Y12 inhibitor (options include clopidogrel, prasugrel, or ticagrelor, chosen based on clinical context).